Andelen af patienter med bivirkninger var 22, 7% og 25, 0% for Bonviva 150 mg én gang om måneden og 21, 5% og 22, 5% for ibandronsyre 2, 5 mg daglig efter henholdsvis et og to år.
The overall proportion of patients who experienced an adverse reaction, was 22.7% and 25.0% for Bonviva 150 mg once monthly and 21.5% and 22.5% for ibandronic acid 2.5 mg daily after one and two years, respectively.